The present invention relates to the electrochemical detection of an analyte by capacitance spectroscopy using a redox active polymer-coated electrode such as a polyaniline-coated electrode.

Mucosal healing is an indication to the disease activity level in patients affected by inflammatory bowel diseases, and it is thus far mainly monitored by endoscopy. Instead or in addition to endoscopy, the invention provides blood test using biomarkers and an index that allows a practitioner to assess the status of mucosal healing, to change or adapt dosage of treatment and to predict which patient will become responder versus non-responder to treatment as assessed by endoscopy. While none of neutrophils cell count, c-reactive protein (CRP), Human type of Cathelicidin (LL-37), or Chitinase 3-like 1 (CHI3L1) alone is able to provide an assessment means of mucosal healing, the invention provides a novel combination of the levels of these biomarkers to assess the level of mucosal healing in relation to endoscopic healing.

Disclosed herein are methods of treating a subject with rheumatoid arthritis (RA) and methods of predicting the subject's likelihood of responding to a new RA therapy. The methods include administering to the subject a composition comprising a macrophage targeting construct and an imaging moiety conjugated thereto to acquiring planar images of a plurality of joints of the subject, and determining at least one TUV.sub.Global value for the subject from the planar images. Covariates comprising the quantification of serological RA markers and/or clinical assessments may be further obtained to apply statistical modeling to the combination of the at least one TUV.sub.Global and the one or more covariates. The statistical modeling is used to determine a likelihood of response to an RA therapy, and a treatment is administered to the subject based on the likelihood of response to the RA therapy.

The present invention relates to a method for diagnosing a recent paroxysmal atrial fibrillation. The method is based on the determination of the at least one marker selected from the group consisting of a cardiac Troponin, NT-proBNP (N-terminal prohormone of brain natriuretic peptide), hsCRP, IL-6 (Interleukin-6) and IGFBP7 (Insulin like growth factor binding protein 7) in a sample from the subject, and on the comparison of the, thus, determined amount(s) with a reference amount (reference amounts). Further, the present invention relates to a method for identifying a subject being treatable with anticoagulation therapy. Further envisaged are systems, reagents and kits used in performing the methods disclosed herein.

The present disclosure relates to the treatment of infection with coronaviruses with granulocyte-macrophage colony-stimulating factor.

The present invention discloses a pencil-like optical fiber sensor probe, including an inner tube, a light screening casing, a clamping device, an optical fiber and an optical probe; a portable immunosensor, including the pencil-like optical fiber sensor probe, an immersion immune response reagent strip, a touch-screen computer, a compact battery-powered sensitive photon counting detector and a case; and a use of the immunosens in detecting inflammatory markers. The design of the pencil-like optical sensor probe greatly simplifies the immune analysis process by combining the immersion immune response reagent strip. Each optical probe allows for up to 10 immunoassays, which reduces the experimental cost and avoids frequent replacement of the probe. The integrated detecting system is powered by battery which is suitable for in-situ analysis and detection. The sensor also has a high stability and sensitivity.

The present application relates to a sensing method that is carried out using an electrode that comprises an electrode substrate functionalised with sensing elements. The method involves conducting electrochemical impedance spectroscopy at a plurality of applied voltages and then integrating measurement data as a function of voltage. Also provided is an apparatus for carrying out the sensing method. The method and apparatus are suitable for a broad range of sensing applications, including the detection of diagnostic biomarkers, drug screening, development of glycoarray systems and the sensing of environmental parameters such as light intensity, temperature and humidity.

The invention relates to using cell free nucleosome levels to identify patients at risk of developing a NETosis associated adverse reaction to the infection. The methods are used to monitor the progress of a disease and assigning a risk of an adverse outcome in a patient suffering from an infection.

The precision of a lateral flow assay for determining the concentration of an analyte in the plasma fraction of a sample of whole blood can be significantly improved by applying an integrated step for determining the hematocrit of the optionally diluted sample, and taking both hematocrit and dilution factor into account when calculating the concentration of the analyte. This is made possible inter alia by using a predetermined wavelength when taking an image of the sample after application to a substrate in the lateral flow assay device, and wherein said wavelength is selected based on the dilution factor used. This hematocrit measurement is advantageously integrated in lateral flow assay methods and devices for the measurement of an analyte in plasma and contributes significantly to an improved precision of such assays.

Analytical assay reaction cartridges, kits containing same, and methods of production and use thereof are disclosed. These cartridges include a magnetic assembly that surrounds at least a portion of a sample read window on the cartridge. The cartridge also includes an analytical reagent positioned therewithin, wherein the analytical reagent comprises magnetic beads coated with at least one anti-red blood cell antibody.